INT-767

INT-767 is a semisynthetic bile acid derivative and small molecule that acts as a dual agonist of the farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5/GPBAR1). It was developed by Intercept Pharmaceuticals for the treatment of fibrotic and metabolic diseases. Preclinical studies have shown that INT-767 can prevent and reverse organ damage due to fibrosis, modulate bile acid composition, reduce inflammation, improve metabolic parameters such as cholesterol and triglyceride levels in animal models, and protect against ischemia-reperfusion injury. The drug is more potent than obeticholic acid at FXR activation and has demonstrated both prophylactic and therapeutic effects in models of advanced steatohepatitis with progressive fibrosis[1][2][4][6][8].